Chimeric epitope vaccine against Leptospira interrogans infection and induced specific immunity in guinea pigs
© The Author(s). 2016
Accepted: 27 September 2016
Published: 14 October 2016
Leptospirosis is an important reemerging zoonosis, with more than half a million cases reported annually, and is caused by pathogenic Leptospira species. Development of a universal vaccine is one of the major strategic goals to overcome the disease burden of leptospirosis. In this study, a chimeric multi-epitope protein-based vaccine was designed and tested for its potency to induce a specific immune response and provide protection against L. interrogans infection.
The protein, containing four repeats of six T- and B-cell combined epitopes from the leptospiral outer membrane proteins, OmpL1, LipL32 and LipL21, was expressed and purified. Western blot analysis showed that the recombinant protein (named r4R) mainly expressed in a soluble pattern, and reacted with antibodies raised in rabbit against heat-killed Leptospira and in guinea pigs against the r4R vaccine. Microscopic agglutination tests showed that r4R antisera was immunological cross-reactive with a range of Chinese standard reference strains of Leptospira belonging to different serogroups. In guinea pigs, the r4R vaccine induced a Th1-biased immune response, as reflected by the IgG2a/IgG1 ratio and cytokine production of stimulated splenocytes derived from immunized animals. Finally, r4R-immunized guinea pigs showed increased survival of lethal Leptospira challenges compared with PBS-immunized animals and tissue damage and leptospiral colonization of the kidney were reduced.
The multi-epitope chimeric r4R protein is a promising antigen for the development of a universal cross-reactive vaccine against leptospirosis.
KeywordsLeptospira Outer membrane protein Multi-epitope Vaccine Cross protection
Leptospira interrogans is the causative agent of zoonotic leptospirosis, which affects humans in both developing and developed countries. It is a major public health problem in many areas, particularly after floods and heavy monsoons. Globally, it has is estimated that 0.1 to 1 per 100,000 people living in temperate climates are affected each year, with the numbers increasing to ten or more per 100,000 people living in tropical climates (according to World Health Organization, The Global Burden of Leptospirosis). In China, between 2002 and 2007 approximately 1500 people were infected with L. interrogans of which 50 died . People are generally infected by contaminated water or soil sources through exposure of wounds in the skin or through exposure of the mucosal layers . The symptoms following infection can vary from a mild febrile illness to more severe icteric disease, which is characterized by potentially fetal renal and liver failure .
Despite the constant progress of antimicrobial therapeutics, vaccination is still expected to be the most effective method to protect people that come in close contact with infected animals or environments. Both inactivated and attenuated vaccines have been used in animals or even in humans. However, these vaccines are associated with high rates of side-effects, such as aches and anaphylaxis, and they confer only short-term serovar-specific immunity [4, 5]. Currently, studies on developing leptospirosis subunit vaccines are particularly focused on bacterial motility, lipopolysaccharides (LPSs), lipoproteins, outer-membrane proteins (OMPs) and potential virulence factors. However, the protective efficacy of these candidates in experimental animals is low (40–75 %) . Thus far, the most promising subunit vaccine candidates are the Lig proteins, which have been shown to confer high-level protection, approaching 100 % in mice and hamsters [7–10]. However, whether the Lig proteins are able to elicit cross-protective immunity to a range of serovar remains to be determined, since the similarity of the amino acid sequence of this protein between different Leptospira spp. is 70–100 % . Since the currently available vaccines are characterized by a short duration of immunity, side-effects or serovar specificity, it is important to develop a universal leptospirosis vaccine with high efficiency and low toxicity.
For this purpose, we screened different Leptospira serotypes for conserved surface-exposed antigens. Bacterial outer membrane proteins (OMPs) are a major target of the immune system in a variety of infectious diseases and they have been suggested as candidates for diagnosis and immunization . In Leptospira, three classes of these OMPs have been identified: 1) lipoproteins, which are the most abundant class and include proteins such as LipL32, LipL41 and LipL21 [11–13]; 2) trans-membrane proteins, which include OmpL1 ; and 3) peripheral membrane proteins, which include LipL45 . In our previously studies we have identified that OmpL1, LipL32 and LipL21 are expressed in all the pathogenic strains of 15 serovar/serogroup standard reference strains of Leptospira in China [16–18]. Furthermore, production of these proteins was down-regulated (about 10–50 fold) in host-adapted Leptospira , suggesting that these proteins might not be involved in the pathogenesis of Leptospira after it gains entry into the mammalian host, which indicates that these OMPs are safe vaccine candidates.
Leptospira contains over 200 pathogenic serovars, which are divided over 25 serogroups. The diversity of Leptospira is also reflected in its OMPs, which are genetically diverse between different serogroups [16–18]. In addition, given the large size of OMPs, conserved epitopes might also be sterically blocked. For these reasons, an OMP vaccine might still provide only minimal protection against a heterologous Leptospira infection. Alternatively, conserved functional OMP epitopes could be used for the development of a peptide vaccine . However, it is difficult to develop an epitope-based peptide vaccine for human clinical trials, because of the technical limitations or economic reasons in synthesizing large quantities of highly purified peptides. Our strategy to overcome these difficulties was to develop a multi-epitope chimeric protein that is composed of the immunodominant epitopes from the OMPs OmpL1, LipL32 and LipL21, which are separated by a tetraglycine linker. The selected epitopes consisted of both B-cell epitopes, which are essential for protective antibody response, and T-cell epitopes, which serve to induce a cellular immune response.
Expression, purification and immunogenicity of the chimeric r4R protein
To evaluate reactivity of r4R with antibodies raised in rabbits against heat-killed L. interrogans strain Lai, Western blot analysis was performed. Antibodies raised in rabbits against heat-killed L. interrogans were showing a strong interaction with r4R (Fig. 1b), indicating that the epitopes of r4R are present on the surface of L. interrogans. To evaluate the immunogenicity of r4R, guinea pigs were immunized with r4R and the collected serum analyzed. Western analysis showed that the chimeric multi-epitope r4R protein was able to induce an antigen-specific humoral immune response (Fig. 1c). The immunodiffusion titer of the antisera against the chimeric r4R protein was 1:8.
MAT analysis of sera from r4R-immunized guinea pigs against various L. interrogans serogroups
MAT titer (1:N)
Lymphocyte proliferation and cytokine production in response to chimeric r4R protein
Protective efficacy of the chimeric r4R protein vaccine
L. interrogans is a bacterial pathogen that causes widespread disease in both animals and humans. Leptospirosis poses a significant public health problem since it is potentially fatal due to the damage it can cause to multiple organs, including the liver, lungs, kidney and brain . Leptospirosis is prevalent throughout China, except for some of the Western provinces (Xinjiang, Xizang, Qinghai, Gansu and Ningxia). Particularly hard hit are the regions in the Yangtze River basin, such as the provinces Sichuan, Hubei and Hunan and the area south of the Five Ridges. The most commonly encountered L. interrogans serogroups in China are Icterohaemorrhagiae, Pomona, Canicola, Hebdomadis, Autumnalis, Grippotyphosa and Australis . The currently available and widely used vaccine against leptospirosis is a multivalent inactivated whole-cell vaccine. However, this vaccine shows high side-effects and elicits little cross-protection against strains from different serovars. Therefore, a new effective and safe vaccine that is able to provide cross-protection of at risk humans or animals is urgently needed.
Currently, vaccine research against Leptospira is focused on the discovery of cross-reactive conserved antigens that are able to provide long-term protection against a broad range of Leptospira spp. . It is well established that OMPs show a high degree of conservation in Leptospira spp.. Furthermore, they are immunodominant antigens in both humans and animals and contain multiple B- and T-cell epitopes that are able to elicit both neutralizing antibody response and T-cell mediated immunity . Therefore, OMPs are likely the most successful candidate antigens for potential subunit vaccines. An ideal peptide-based vaccine should also contain both B- and T-cell epitopes. In our previous research, we identified six B- and T-cell combined immunodominant epitopes in the OMPs OmpL1, LipL32 and LipL21 from Leptospira, and tested whether they were able to induce specific immune responses [21, 22]. Considering the diversity among Leptospira serovars, these epitopes fragments are much conserved and show a high degree of homology among 15 serovar/serogroup standard reference strains of Leptospira in China. These six selected epitopes are only about 20 amino acids in length, which complicates mass production and makes them susceptible to host hydrolysis mechanisms. Therefore, in the current study, a gene fragment was synthesized that encoded all six epitopes separated by a four glycine spacer and which was codon optimized for expression in E. coli. This gene fragment was cloned as four consecutive copies in an expression vector and produced a 64 kD fusion protein. This recombinant protein was expressed in the soluble fraction, which is important to maintain its antigenicity and immunogenicity.
Antibodies are a major contributor to the phagocytosis and destruction of pathogenic Leptospira by macrophages . Our r4R protein showed a strong immunogenicity in guinea pigs, which resulted in the production of high levels of specific antibodies. This is essential for the killing of Leptospira through complement-mediated lysis or through opsonin-dependent phagocytosis. To confirm that antibodies were reactive with a variety of leptospiral serovars, the MAT test was used, which is considered as the “golden standard” in the serodiagnosis of leptospirosis and the serological classification of Leptospira species. Our results revealed that the antisera obtained after immunization with r4R were able to agglutinate all standard reference strains of Leptospira in China, with MAT titers up to 1:320. Therefore, we expect that antibodies raised against our r4R protein are able to provide cross-protection against a wide variety of Leptospira serovars, although this still requires further confirmation using animal experiments.
Protective immunity to Leptospira is highly serovar-specific, which points to a dominant role for humoral immunity in the protection against Leptospira infection. However, recently it was shown that during an infection with Leptospira, cellular immunity still plays an important role in the control of disease . Immunization with our r4R multi-epitope chimeric protein resulted in a dominant Th1 response, which was reflected by the yield of antigen-specific IgG subtypes (IgG2a > IgG1). A Th1 response generally induces IgG2a expression, while a Th2 response results predominantly in IgG1 production . Besides mediating intracellular killing of a variety of pathogenic microorganisms, Th1 cells also stimulate B cells to produce antibodies that are important for mucosal immunity, such as IgM, IgG2a and IgA [29, 30], which is regulated via secretion of IFN-γ and IL-2 and via expression of CD40L . Cytokine measurements in the culture supernatant of splenocytes from immunized guinea pigs, after stimulation with our r4R protein, showed high induction of IFN-γ compared with IL-4, which supports that the r4R multi-epitope chimeric protein vaccine is biased towards a Th1-type response.
Severe leptospirosis is typically associated with an overactive host response that damages its own tissues, such as the liver, kidney and lung, which can furthermore lead to hemorrhages. Guinea pigs are susceptible to Leptospira infection and frequently present these symptoms. In order to determine the ability of our r4R protein to induce a protective immune response against a Leptospira infection, guinea pigs were used as an infection model. Compared with unvaccinated guinea pigs, immunized animals showed increased survival, reduced tissue damage, decreased colonization of the kidneys and reduced shedding of Leptospira in the urine. However, immunized guinea pigs also showed some inflammatory reactions, such as edema symptoms. This may be the result of increased IFN-γ production after immunization, which can cause inflammation or a delayed type hypersensitivity .
This study showed that the chimeric multi-epitope protein r4R is a promising vaccine candidate for the development of a universal vaccine against Leptospira infections. Immunized guinea pigs showed a strong antigen-specific humoral and cellular immune response, a reduction in tissue damage and colonization and protection against a lethal Leptospira infection. Thus, the multi-epitope chimeric r4R vaccine, containing both T- and B-cell epitopes, may represent an effective antigen to increase the efficacy of vaccines against leptospirosis.
Bacterial strains, media and plasmids
Escherichia coli host strains DH10B and BL21 (DE3) and the plasmids pBacPAK8 and pET-28a (+) were maintained in the lab. The pGEM-T easy vector was obtained from Promega (Wisconsin, USA). Endonucleases and the DNA ladder were bought from TaKaRa Bio Co., Ltd (Dalian, China). The protein molecular weight marker, lymphocyte separation medium (guinea pig), mitomycin and the CCK-8 kit were purchased from Beyotime Institute of Biotechnology (Jiangsu, China). All chemicals were of analytical grade. The secondary antibody-enzyme conjugates used in this study were obtained from Jackson ImmunoResearch (Pennsylvania, USA) or Santa Cruz (California, USA). The UltraEAL Western Blot Detection System was purchased from Shanghai Generay Biotech Co., Ltd (Shanghai, China). Sera from rabbits immunized with inactivated L. interrogans serovar Icterohaemorrhagiae Lai were maintained in our lab [16, 24, 33]. Leptospira strains are kept in our lab and cultured in EMHJ medium at 28 °C. New Zealand white rabbits were purchased from the Laboratory Animal Center of Zhejiang University. Three-week-old guinea pigs were purchased from Vital River Laboratories (Beijing, China) and screened by the microscopic agglutination test to ensure that they were free of preexisting antibodies to Leptospira.
Design, expression and purification of chimeric peptide
Based on our previous studies, six OMP epitopes were selected, which each were 11–27 amino acids in length (Additional file 2) [21, 22]. Recombinant plasmids were constructed and target proteins were expressed and purified following methods published previously . Briefly, a gene encoding six selected immunodominant epitopes, which were spaced by a tetraglycine linker and codon-optimized for E. coli translation, was synthesized. In the 5′ end, a BamHI site was designed, and in the 3′ end, a BglII and an EcoRI site were designed and spaced by the terminator sequence TAA. Through four time consecutive cloning of the BamHI/EcoRI-digested gene into its BglII/EcoRI site, the synthesized gene was repeated in four copies in the plasmid pBacPAK8-4R as a single gene. The multi-epitope gene was subsequently cloned into the BamHI/EcoRI site of pET28a (pET28a-4R). Plasmid DNA of pET28a-4R was transformed into E. coli BL21 (DE3) for protein expression. The recombinant protein was expressed and purified using Ni-NTA Superflow resin (Biocolors, Shanghai, China). Possible endotoxin contamination from E. coli BL21 (DE3) was removed from the purified protein using the Detoxi-Gel Endotoxin Removal kit (Thermo Scientific, USA) . Using LPS from E. coli serotype O111:B4 (Sigma) as control, a limulus test was carried out to detect LPS in the purified protein samples according to the manufacturer’s protocol.
SDS-PAGE and Western blot for the detection of chimeric antigens
To detect the recombinant 4R protein with antibodies present in the serum of rabbits immunized with inactivated L. interrogans cells, the purified target protein was run on a 10 % SDS-PAGE gel, along with appropriate controls and prestained protein markers. The proteins were subsequently transferred to a polyvinylidene fluoride membrane (PVDF, Millpore) following Bio-Rad Protocols. The membrane was incubated in 1 × TBST (Tris buffered saline; 0.1 % Tween 20, pH 7.2) with 6 % newborn bovine serum for 1 h at 37 °C, washed three times with 1 × TBST and further incubated with rabbit anti-Leptospira serum (1:1 000 dilution) for 1 h at 37 °C. The membrane was washed three times with 1 × TBST, and incubated with a goat anti-rabbit IgG-HRP conjugate secondary antibody (1:5 000 dilution) for a further 1 h at 37 °C. Chemiluminescent detection was performed using Lumigen-PS according to the manufacturer’s protocol (GE) and blots were exposed against X-ray films for relevant time periods.
Immunization of guinea pigs with purified recombinant 4R (r4R) protein and detection of the antibody response
For the safety test, guinea pigs (150 g ± 3 g, aged 3 weeks), were immunized with 200 μg r4R protein that had been pre-mixed with aluminum hydroxide (1.0 mg/ml, Sigma, USA). Administration was performed subcutaneously in the four limbs and an equivalent booster dose was given 14 days after the initial immunization. After 7–10 days, guinea pigs were sacrificed for further experiments. PBS immunized guinea pigs following the same procedure were used as control.
The immunogenicity of the r4R protein was analyzed by Western blot and ELISA. Blood collected from immunized guinea pigs was allowed to clot overnight, centrifuged at 4500 rpm for 10 min and the sera were collected and stored at −20 °C for further analysis. Western blot analysis was carried out as described above using a 1:150 dilution of sera from r4R-immunized animals and a 1:5000 dilution of the goat anti-guinea pig IgG-HRP conjugate secondary antibody.
For ELISA analysis, 96-well ELISA plates were coated with 0.5 μg/well of L. interrogans strain Lai diluted in 0.1 M Na2HPO4 (pH 9.0). After incubation overnight at 4 °C, the plates were washed three times with PBST (phosphate-buffered saline containing 0.05 % Tween 20, pH 7.4), blocked at 37 °C for 1 h with 100 μl of 1 % bovine serum albumin (BSA) in PBS, and washed three times with PBST. One hundred microliter optimal diluted (1:100) serum sample was added to each well and incubated at 37 °C for 2 h. After washing, 100 μl of goat anti-guinea pig IgG1 or IgG2a conjugated to horseradish peroxidase (ICLLab) diluted (1:100) with 1 % BSA in PBST was added to plates and incubated at 37 °C for 1 h. Following washing, 100 μl of concentrated 3,3′,5,5′-tetramethylbenzidine substrate was allowed to react with the HRP for 15 min at 37 °C in the dark. The color reaction was stopped by adding 100 μl of 2 M H2SO4, and the absorbance at a wavelength of 450 nm was read in a microplate reader.
MAT was used to detect the agglutination of immune sera with standard reference strains of Leptospira in China . Briefly, the sera from immunized guinea pigs were diluted in a gradient (1:20, 1:40, 1:80, 1:160, 1:320 and 1:640) in normal saline and subsequently mixed with the same volume of Leptospira cultures. After incubated at 37 °C for 1 h, agglutination was determined by dark-field microscopy. The agglutination titer was determined as the highest dilution of serum which causes 50 % of the Leptospira to agglutinate compared with the negative control.
LD50 determination and challenge experiments
L. interrogans strain Lai was propagated for 3 weeks in EMJH medium until dense cultures were observed using dark-field microscopy. The Leptospira were washed three times by centrifugation at 12,000 rpm for 15 min and resuspended in PBS. The suspension was then diluted to concentrations ranging from 1 × 107 to 1 × 1010 cells/ml. To calculate the 50 % lethal dose (LD50), guinea pigs were divided into five groups, each containing six guinea pigs. Four of the groups were given different concentrations of fresh Leptospira (107, 108, 109 and 1010 cells/ml)) intraperitoneally in 1 ml quantities. The animals of the control group were administered with EMJH. The animals were monitored twice daily for up to 21 days post challenge to record for signs of terminal disease (moribund), which was counted as dead. The surviving animals were recorded for calculating the LD50 using the probit analysis . In the vaccine trial, the guinea pigs were divided into three groups, each with five animals. Animals from A group were used as unvaccinated healthy controls. Animals from group B were immunized with 200 μg r4R protein supplemented with aluminum hydroxide (1.0 mg/ml. Sigma, USA) as adjuvant. Booster doses of the same vaccine were given at 2 week intervals. Animals from group C were immunized with PBS and used as control animals. The guinea pigs in group B and C were challenged intraperitoneally with a 2 × LD50 of low-passage L. interrogans strain Lai 42 days after the initial immunization. The animals were monitored twice daily to observe for clinical symptoms. Urine samples, which were collected at weekly intervals following challenge, were processed for the detection of Leptospira. All animals were sacrificed and blood was collected from the eyeground for antibody detection. The tissues, including liver, kidney, spleen and lungs were collected aseptically for further analysis. The protective efficacy of the chimeric protein was replicated three times.
The kidneys of infected animals were homogenized in EMJH medium and subsequently transferred into 5 ml EMJH medium. After incubation at 30 °C for 28 days, the culture samples were monitored for growth. A tungsten lamp was used to determine the turbidity of the EMJH medium and after Fontana silver staining, the samples were observed using an optical microscope.
Tissues from guinea pigs were immersed in 10 % neutral formaldehyde solution for 48 h, and then rinsed, dehydrated and embedded in paraffin. Tissue sections were stained with hematoxylin and eosin (H&E) using standard histological techniques, and examined by light microscopy [8, 37].
CD4+ T lymphocyte proliferative response and cytokine evaluation
Spleens were aseptically removed from immunized guinea pigs and mechanically homogenized with a syringe plunger. The splenic T lymphocytes were isolated using lymphocyte separation medium (guinea pig) according to the manufacturer’s protocols, and the cells were suspended in complete RPMI-1640 media (RPMI-1640, 10 % fetal bovine serum, 2 mM glutamine, 50 U of penicillin/ml, 50 μg of streptomycin/ml, 50 μM 2-mercaptoethanol, and 25 mM HEPES).
Lymphocyte proliferation was evaluated using the CCK-8 assay kit as described previously . Aliquots of 5 × 105 splenic lymphocytes were dispensed into 96-well flat-bottomed microtiter plates and incubated at 37 °C with 5 % CO2 for 7 days in the presence of 5 μg pokeweed mitogen/ml and 2 μg purified r4R protein. Cells suspended in PBS were used as negative control, and the mitogen Concanavalin A (ConA, at a final concentration of 1 μg/ml) was used as positive control.
To determine the cytokine secretion pattern and evaluate Th cell polarization, cytokine levels in the supernatant of the cell culture (100 μl each) were evaluated using guinea pig IFN-γ or IL-4 ELISA kits (Westang, Shanghai). The cytokine levels were calculated by titration of supplied calibrated cytokine standards. All assays were performed as suggested by the manufacturer. The level of cytokines in the medium was calculated for each sample by subtracting the corresponding cytokine concentration produced in the control wells without antigen.
Figures represent data from three independent experiments, and the data were expressed as mean ± standard deviation (S.D.). Microsoft office Excel was used to analyze variance and identify significant differences.
We are deeply indebted to Professor Stijn van der Veen (Zhejiang University) for his strict and helpful reading of the manuscript.
This work was supported by funding from the National Natural Science Foundation of China (81271781).
Availability of data and materials
The datasets supporting the conclusions of this article are included within the manuscript.
LXA designed the work, performed the research study, and drafted the manuscript. XGH and KLL participated in experimental work. LDJ and SD participated in the protection and histopathological experiments. CX performed the Fontana silver staining experiments. YJ designed and supervised the research study. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
All authors have consented to the publication of this manuscript.
Ethics approval and consent to participate
All animals were kept under specific-pathogen-free conditions during the experiment. The animal experiments were approved by the Institutional Review Board at Zhejiang University.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Wang Z, Jin L, Wegrzyn A. Leptospirosis vaccines. Microb Cell Fact. 2007;6:39.View ArticlePubMedPubMed CentralGoogle Scholar
- Bharti AR, Nally JE, Ricaldi JN, Matthias MA, Diaz MM, Lovett MA, Levett PN, Gilman RH, Willig MR, Gotuzzo E, Vinetz JM. Peru-United States Leptospirosis Consortium. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis. 2003;3(12):757–71.View ArticlePubMedGoogle Scholar
- McBride AJ, Athanazio DA, Reis MG, Ko AI. Leptospirosis. Curr Opin Infect Dis. 2005;18:376–86.View ArticlePubMedGoogle Scholar
- Faine S, Adher B, Bloin C, Perolat P. Leptospira and leptospirosis. 2nd ed. Melbourne: MedSci; 1999.Google Scholar
- Yan J, Dai BM, Yu ES. Leptospirosis. 3rd ed. Beijing: People’s Medical Publishing House; 2006.Google Scholar
- Ko AI, Goarant C, Picardeau M. Leptospira: the dawn of the molecular genetics era for an emerging zoonotic pathogen. Nat Rev Microbiol. 2009;7(10):736–47.View ArticlePubMedPubMed CentralGoogle Scholar
- Koizumi N, Watanabe H. Leptospiral immunoglobulin-like proteins elicit protective immunity. Vaccine. 2004;22:1545–52.View ArticlePubMedGoogle Scholar
- Palaniappan RU, McDonough SP, Divers TJ, Chen CS, Pan MJ, Matsumoto M, Chang YF. Immunoprotection of recombinant leptospiral immunoglobulin-like protein A against Leptospira interrogans serovar Pomona infection. Infect Immun. 2006;74:1745–50.View ArticlePubMedPubMed CentralGoogle Scholar
- Silva EF, Medeiros MA, McBride AJ, Matsunaga J, Esteves GS, Ramos JG, Santos CS, Croda J, Homma A, Dellagostin OA, Haake DA, Reis MG, Ko AI. The terminal portion of leptospiral immunoglobulin-like protein LigA confers protective immunity against lethal infection in the hamster model of leptospirosis. Vaccine. 2007;25:6277–86.View ArticlePubMedPubMed CentralGoogle Scholar
- Yan W, Faisal SM, McDonough SP, Divers TJ, Barr SC, Chang CF, Pan MJ, Chang YF. Immunogenicity and protective efficacy of recombinant Leptospira immunoglobulin-like protein B (rLigB) in a hamster challenge model. Microbes Infect. 2009;11:230–7.View ArticlePubMedGoogle Scholar
- Cullen PA, Haake DA, Bulach DM, Zuerner RL, Adler B. LipL21 is a novel surface-exposed lipoprotein of pathogenic Leptospira species. Infect Immun. 2003;71:2414–21.View ArticlePubMedPubMed CentralGoogle Scholar
- Haake DA, Chao G, Zuerner RL, Barnett JK, Barnett D, Mazel M, Matsunaga J, Levett PN, Bolin CA. The leptospiral major outer membrane protein LipL32 is a lipoprotein expressed during mammalian infection. Infect Immun. 2000;68:2276–85.View ArticlePubMedPubMed CentralGoogle Scholar
- Shang ES, Summers TA, Haake DA. Molecular cloning and sequence analysis of the gene encoding LipL41, a surface-exposed lipoprotein of pathogenic Leptospira species. Infect Immun. 1996;64:2322–30.PubMedPubMed CentralGoogle Scholar
- Dong H, Hu Y, Xue F, Sun D, Ojcius DM, Mao Y, Yan J. Characterization of the ompL1 gene of pathogenic Leptospira species in China and immunogenicity of the OmpL1 protein. BMC Microbiol. 2008;8:223.View ArticlePubMedPubMed CentralGoogle Scholar
- Matsunaga J, Young TA, Barnett JK, Barnett D, Bolin CA, Haake DA. Novel 45-kilodalton leptospiral protein that is processed to a 31-kilodalton growth-phase-regulated peripheral membrane protein. Infect Immun. 2002;70:323–34.View ArticlePubMedPubMed CentralGoogle Scholar
- Fan XL, Yan J, Mao YF, Li LW, Li SP. Genotypes of the LipL32 gene from the dominant serogroups of Leptospira interrogans in China and construction of the expression system of the gene and immunological identification of the recombinant proteins. Chin J Microbiol Immunol. 2004;24(2):92–7.Google Scholar
- Liu YY, Luo DJ, Yan J. Sequence analysis of lipL 21 genes from the dominant serogroups of Leptospira interrogans prevalent in China and identification of the expression products. Chin J Zoonoses. 2005;21(9):744–7.Google Scholar
- Xu Y, Yan J, Mao YF, Li LW, Li SP. Genotypes of the OmpL1 gene from the dominant serogroups of Leptospira interrogans in China and construction of prokaryotic expression system of the gene and immunological identification of the recombinant protein. Chin J Microbiol Immunol. 2004;24(6):439–44.Google Scholar
- Xue F, Dong H, Wu J, Wu Z, Hu W, Sun A, Troxell B, Yang XF, Yan J. Transcriptional responses of Leptospira interrogans to host innate immunity: significant changes in metabolism, oxygen tolerance, and outer membrane. PLoS Negl Trop Dis. 2010;4(10):e857.View ArticlePubMedPubMed CentralGoogle Scholar
- Tang SS, Tan WS, Devi S, Wang LF, Pang T, Thong KL. Mimotopes of the Vi antigen of Salmonella enterica serovar typhi identified from phage display peptide library. Clin Diagn Lab Immunol. 2003;10:1078–84.PubMedPubMed CentralGoogle Scholar
- Lin X, Zhao J, Qian J, Mao Y, Pan J, Li L, Peng H, Luo Y, Yan J. Identification of immunodominant B- and T-cell combined epitopes in outer membrane lipoproteins LipL32 and LipL21 of Leptospira interrogans. Clin Vaccine Immunol. 2010;17(5):778–83.View ArticlePubMedPubMed CentralGoogle Scholar
- Lin X, Sun A, Ruan P, Zhang Z, Yan J. Characterization of conserved combined T and B cell epitopes in Leptospira interrogans major outer membrane proteins OmpL1 and LipL41. BMC Microbiol. 2011;11(1):21.View ArticlePubMedPubMed CentralGoogle Scholar
- Dutta TK, Christopher M. Leptospirosis-an overview. J Assoc Physicians India. 2005;53:545–51.PubMedGoogle Scholar
- Sonrier C, Branger C, Michel V, Ruvoen-Clouet N, Ganiere JP, Andre-Fontaine G. Evidence of crossprotection within Leptospira interrogans in an experimental model. Vaccine. 2000;19:86–94.View ArticlePubMedGoogle Scholar
- Xu LH, Yan J, Ruan P, Mao YF. Immune functional epitopes and inflammation inducing effects of the major outer envelope proteins of Leptospira interrogans. J Zhejiang Univ (Med Sci). 2005;34:9–14.Google Scholar
- Levett PN. Leptospirosis. Clin Microbiol Rev. 2001;14:296–326.View ArticlePubMedPubMed CentralGoogle Scholar
- Baldwin CL, Hsu H, Chen C, Palmer M, McGill J, Waters WR, Telfer JC. The role of bovine γδ T cells and their WC1 co-receptor in response to bacterial pathogens and promoting vaccine efficacy: a model for cattle and humans. Vet Immunol Immunopathol. 2014;159(3–4):144–55.View ArticlePubMedGoogle Scholar
- Barry MA, Johnston SA. Biological features of genetic immunization. Vaccine. 1997;15:788–91.View ArticlePubMedGoogle Scholar
- Foulds KE, Wu CY, Seder RA. Th1 memory: implications for vaccine development. Immunol Rev. 2006;211:58–66.View ArticlePubMedGoogle Scholar
- Maciolek JA, Pasternak JA, Wilson HL. Metabolism of activated T lymphocytes. Curr Opin Immunol. 2014;27:60–74.View ArticlePubMedGoogle Scholar
- Avramidis N, Victoratos P, Yiangou M, Hadjipetrou-Kourounakis L. Adjuvant regulation of cytokine profile and antibody isotype of immune responses to Mycoplasma agalactiae in mice. Vet Microbiol. 2002;88(4):325–38.View ArticlePubMedGoogle Scholar
- Kita M. Role of IFN-gamma in nonviral infection. Nippon Rinsho. 2006;64(7):1269–74.PubMedGoogle Scholar
- Luo DJ, Hu Y, Sun BL, Tian JX, Hu MD, Yan J. Sequencing and immunoreactive analysis of lipL21 genes with its products from dominant serogroups of Leptospira interrogans in Chin. Chin J Microbiol Immunol. 2006;26(11):979–84.Google Scholar
- Lin XA, Sui YJ, Mao YF, Yan J. Construction of multiple antigenic peptide and the immunity analysis. Chin J Microbiol Immunol. 2008;28(11):1010–3.Google Scholar
- Wang H, Wu YF, Ojcius DM, Sun D, Zhang CL, Ding SB, Lin XA, Yan J. Leptospiral hemolysins induce proinflammatory cytokines through Toll-like receptor 2- and 4-mediated JNK and NF-kB signaling pathways. PLoS One. 2012;7(8):e42266.View ArticlePubMedPubMed CentralGoogle Scholar
- Warren R, Lockman H, Barnewall R, Krile R, Blanco OB, Vasconcelos D, Price J, House RV, Bolanowksi MA, Fellows P. Cynomolgus macaque model for pneumonic plague. Microb Pathog. 2011;50(1):12–22.View ArticlePubMedGoogle Scholar
- Wild CJ, Greenlee JJ, Bolin CA, Barnett JK, Haake DA, Cheville NE. An improved immunohistochemical diagnostic technique for canine leptospirosis using antileptospiral antibodies on renal tissue. J Vet Diagn Invest. 2002;14(1):20–4.View ArticlePubMedPubMed CentralGoogle Scholar